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Abstract
Computational approaches have been major drivers behind the progress of
proteomics in recent years. The aim of this white paper is to provide a
framework for integrating computational proteomics into ELIXIR in the near
future, and thus to broaden the portfolio of omics technologies supported by
this European distributed infrastructure. This white paper is the direct result of a
strategy meeting on ‘The Future of Proteomics in ELIXIR’ that took place in
March 2017 in Tübingen (Germany), and involved representatives of eleven
ELIXIR nodes.
 
These discussions led to a list of priority areas in computational proteomics that
would complement existing activities and close gaps in the portfolio of tools and
services offered by ELIXIR so far. We provide some suggestions on how these
activities could be integrated into ELIXIR’s existing platforms, and how it could
lead to a new ELIXIR use case in proteomics. We also highlight connections to
the related field of metabolomics, where similar activities are ongoing. This
white paper could thus serve as a starting point for the integration of
computational proteomics into ELIXIR. Over the next few months we will be
working closely with all stakeholders involved, and in particular with other
representatives of the proteomics community, to further refine this paper.
 This article is included in the   gateway.ELIXIR
 This article is included in the   gateway.EMBL-EBI
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Introduction
Proteomics is generally defined as the large-scale experimental 
study of the proteome. High-throughput proteomics approaches 
have matured significantly, becoming an increasingly used tool in 
biological research. The rapid development of the field over the 
last decade has been primarily driven by technological progress 
in mass spectrometry instrumentation, chromatographic separa-
tion, genomics (increased availability of sequenced genomes) 
and bioinformatics1,2. The primary workhorse of proteomics 
today is mass spectrometry coupled to liquid chromatography 
(LC-MS), with less commonly used high-throughput proteomics 
approaches based on antibodies (e.g., protein arrays and other 
immunofluorescence-based techniques). Key applications of pro-
teomics are the study of (differential) protein expression in time 
and space, characterization of protein primary structures and their 
post-translational modifications (PTMs), such as phosphorylation 
and glycosylation, elucidating protein structures, and protein- 
protein interactions. It is the primary technology driving progress 
in unravelling signalling networks (e.g. protein phosphorylation 
driven signalling) and protein interaction networks, and is indis-
pensable for understanding biological function of protein isoforms 
and disentangling their specific functions. In complex systems biol-
ogy and systems medicine studies, proteomics often complements 
information gained from other omics levels, such as genomics and 
transcriptomics (the so-called proteogenomics and proteotranscrip-
tomics studies3), metagenomics (metaproteomics), glycomics, and 
metabolomics.
As already highlighted, remarkable advances in computational 
methods have been a key driver in the fast development of the 
field of proteomics. ELIXIR (https://www.elixir-europe.org/) is 
a European Research Infrastructure (ESFRI), which coordinates, 
integrates and sustains bioinformatics resources across its member 
states. Some of the most prominent research groups in proteomics 
are active in Europe, such as Prof. Matthias Mann (Martinsried, 
Munich, Germany), Prof. Ruedi Aebersold (Zurich, Switzerland), 
Prof. Albert Heck (Utrecht, the Netherlands) and Prof. Mathias 
Uhlén (Stockholm, Sweden). In addition, Europe also hosts world-
wide renowned groups that are focused on the development and 
application of widely-used bioinformatics tools and resources, 
including MaxQuant4, the OpenMS framework5, CompOmics6 
tools, such as PeptideShaker7, the PRIDE database, as the world-
leading proteomics repository8 (also coordinating the global 
ProteomeXchange Consortium of proteomics resources9), and a 
collection of open data standards and related software10, empha-
sizing the European leading role in the activities of the HUPO 
(Human Proteome Organisation) Proteomics Standards Initiative 
(PSI).
Outside mass spectrometry proteomics, the Human Protein Atlas11, 
located in Sweden, is the world-leading resource for antibody-
based characterization of the human proteome. In this context, 
it should also be highlighted that two of the three sites behind 
the development of UniProt12, the most-widely used protein 
knowledgebase, are European: the Swiss Institute of Bioinformat-
ics (SIB) and the European Bioinformatics Institute (EMBL-EBI). 
Furthermore, neXtProt13, which is the reference knowledgebase 
for human proteins in the context of the HUPO Human Proteome 
Project, is also developed and maintained at SIB.
Additionally, it is of note to highlight that a number of national 
proteomics-dedicated infrastructures have already prioritised 
structuring and developing computational proteomics among their 
activities. This is the case of the French proteomics infrastruc-
ture ProFI (which has, for instance, devoted a major investment to 
develop the Proline tool) and the Spanish infrastructure ProteoRed 
(which has, for example, contributed heavily to PSI activities). 
Also, proteomics is represented in other national scientific infra-
structures. One example is the Netherlands DTL (Dutch Techcentre 
for Life Sciences), having an active role in advocating for FAIR 
data management.
In the context of providing infrastructure for storing proteomics 
data, it is worth highlighting here that, although it was not the case 
just a few years ago, thanks to many of these efforts, and with the 
support of scientific publishers and funders, public availability of 
proteomics data has increased exponentially in recent years, becom-
ing a common scientific practise, similarly to how it routinely hap-
pens in disciplines such as genomics and transcriptomics14. Figure 1 
summarises the growth of the PRIDE database in recent years.
Although the European bioinformatics community has been very 
active in the proteomics field (see above), proteomics activities 
have not been highly represented in ELIXIR so far. There was a 
proteomics component in two small ELIXIR pilot actions (col-
laborations between EMBL-EBI, now ELIXIR central node, and 
Bioinformatics Services to Swedish Life Science [BILS], now 
ELIXIR-Sweden). In addition, a selection of proteomics tools and 
training events have been included in the ELIXIR tool registry15 
(http://bio.tools) and in TeSS, the ELIXIR training portal (https://
tess.elixir-europe.org/), respectively. These platforms were recently 
presented to the proteomics community16. However, we propose 
that, due to the growing importance of the field and the prominence 
of proteomics bioinformatics activities in Europe, it is the right 
time to formally integrate proteomics activities in ELIXIR.
In this context, in February 2017, EMBL-EBI and ELIXIR-DE 
initiated the first ELIXIR ‘Implementation study’ involving pro-
teomics approaches, as a starting point for the field. Within this 
implementation study, suggested by ELIXIR management, the 
meeting “The future of proteomics in ELIXIR” took place in 
Tübingen (Germany), as a general strategy meeting for future pro-
teomics activities in ELIXIR. In this white paper, we first summa-
rize the main conclusions of the meeting, and then explain possible 
future directions for the incorporation of proteomics activities in 
ELIXIR, taking into account the current overall ELIXIR structure, 
split in platforms and use cases.
Methods
Meeting “The future of proteomics in ELIXIR”
The meeting took place on March 1st–2nd 2017 in Tübingen 
(Germany). Attendance was widely advertised through ELIXIR 
dissemination channels (e.g., mailing lists, newsletter) and was 
open to any interested member of the community. There were 
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Figure 1. Number of datasets (A), and the total size of the PRIDE database (B), from 2005 to 2016. Data was retrieved directly from the PRIDE 
Archive OracleTM database instance, which contains the file sizes and the dates when the datasets where originally submitted.
24 attendees representing eleven ELIXIR nodes: Germany (host), 
Belgium, Czech Republic, Denmark, France, Italy, Netherlands, 
Sweden, Switzerland, EMBL-EBI, and one representative from the 
ELIXIR Hub. The detailed minutes of the meeting are available as 
Supplementary File 1. The meeting started with a presentation 
given by Rafael Jiménez (ELIXIR Chief Technical Officer) who 
provided a general overview of the current ELIXIR activities. 
This initial talk was followed by a series of presentations where 
the representatives of each node summarized their ongoing 
activities related to proteomics. All the presentations are freely 
available at http://tinyurl.com/elixir-proteomics.
The remainder of the meeting was devoted to an open discussion 
on how to bring together activities, experience, stakeholders, and 
emerging needs. First of all, ten potential ELIXIR stakeholders in 
this domain were identified, namely: funding agencies, regulatory 
bodies, educators, infrastructures, publishers, core facilities, bio-
informaticians, life scientists, industries and hospitals/patients. 
Second, a series of needs and challenges were outlined for each of 
the stakeholders, and these were then mapped to each of the exist-
ing ELIXIR platforms: Data, Tools, Interoperability, Compute and 
Training (see below). The output of this activity is summarized in 
Supplementary Table 1. In the second day of the meeting, more 
concrete topics, derived from the identified needs and challenges 
were outlined by the attendees, and then organised in wider areas, 
so called “clusters”. Finally, they were prioritised, with the idea 
that these could form the basis for future proteomics activities in 
ELIXIR.
Current ELIXIR internal structure
Here we describe the current status of ELIXIR platforms and use 
cases, by May 2017. ELIXIR’s activities are structured around 
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platforms and use cases. They bring together resources and exper-
tise from the ELIXIR Nodes and form the basic unit of operation 
within ELIXIR. The ELIXIR platforms are responsible of the 
implementation of the ELIXIR programme and are organised in 
five key areas: Data, Tools, Compute, Interoperability and Training. 
The platforms are complemented by four use cases that represent 
four scientific communities: Human data, Rare diseases, Marine 
metagenomics and Plant sciences (Figure 2). The use cases drive 
the work of the ELIXIR platforms by defining their bioinformat-
ics needs and requirements. The close collaboration between the 
ELIXIR use cases and platforms ensures that the services developed 
by the ELIXIR platforms are fit for purpose. Each platform and 
use case is led by a group of senior scientists from across the 
ELIXIR nodes. In addition to the funding available in each national 
ELIXIR node, the main source of financial support for ELIXIR 
activities comes from the ELIXIR-EXCELERATE EU H2020 
project.  Additional activities are funded through other complemen-
tary grants as well as ‘Implementation studies’ supported by the 
ELIXIR Hub.
The ELIXIR platforms. The Data platform focuses on sustaining 
Europe’s life science data infrastructure. This platform is work-
ing on guidelines and indicators for data resources to improve 
their impact and sustainability17. It also works on improving links 
between curated data resources and literature data.
The Tools platform is dedicated to services and connectors to drive 
access and exploitation of bioinformatics research software. The 
main key activities within this platform are centred to facilitate the 
discovery, benchmarking and interoperability of software. It does 
also focus on software development best practices, as well as on a 
strategy for workflows and software containers.
The Interoperability platform supports the discovery, integration 
and analysis of biological data. Activities driven by this platform 
are organised in projects around identifiers, metadata standards and 
linked data. It also works on the description of interoperability serv-
ices as well as specialised workshops named BYOD (Bring Your 
Own Data)18 to improve the “FAIRness” (Findable, Accessible, 
Interoperable and Re-usable) of data resources19.
The Compute platform is dedicated to the compute, storage, trans-
fer, authentication and authorization of biological data relying on 
services provided by ELIXIR nodes and e-infrastructures. Finally, 
the Training platform aims to increase the professional skills for 
managing and exploiting data. Part of activities are meant to train 
researchers, trainers and service providers, but it also includes other 
activities related to e-learning, to improve the discovery and avail-
ability of training materials and to measure the impact of training.
Current ELIXIR use cases. There are four use cases. First of all, 
the Human data use case develops long-term strategies for man-
aging and accessing sensitive human data. The Rare diseases use 
case supports the development of new therapies for rare diseases. 
The Marine metagenomics use case works towards a sustainable 
metagenomics infrastructure to nurture research and innovation in 
the marine domain. Finally, the Plant sciences use case develops 
an infrastructure to support genotype-phenotype analysis for crop 
and tree species.
Results and discussion
Areas prioritised in the meeting
In an attempt to assess the relative priorities of the various areas 
of proteomics that might steer integration into ELIXIR, attendees 
voted on the relative importance of the topics. The following list 
shows the top-ranked areas for future ELIXIR related proteomics 
activities (called “Clusters” from now on), sorted in descending 
order by the number of votes received:
Cluster 1. Multi-omics approaches. It includes topics such as data 
integration of proteomics and other types of omics data, correla-
tion between gene and protein expression, and development of data 
standards for “multi-omics” data types. A closely related group of 
activities was “Cancer proteomics”, comprising topics such as sup-
port for clinical proteomics data (including large patient cohorts) 
and cancer “multi-omics” (proteogenomics) studies.
Figure 2. Overview of current ELIXIR platforms and use cases (by May 2017).
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Cluster 2. Proteoforms and PTMs. The term proteoform20 repre-
sents the different molecular forms in which the protein product of 
a single gene can be found, including changes due to genetic varia-
tions, alternatively spliced RNA transcripts and PTMs, among other 
events. This cluster of activities included topics such as the han-
dling, validation of proteoforms and creation of standards for their 
description, improvement of the existing connection between pro-
teoforms, genes and metabolites (topic related to Cluster 1 above), 
and activities devoted to explain unidentified spectral signals.
Cluster 3. Quality Control (QC) activities. In any analytical disci-
pline, QC is essential. Due to the fact that proteomics is a newer and 
still rapidly developing field, QC has historically not been as well-
developed in proteomics as in, for instance, the more established 
small molecule mass spectrometry field14. This cluster is therefore 
focused on activities to develop automatic and reliable pipelines for 
QC of proteomics data at different levels.
Cluster 4. Data analysis workflows and cloud computing. The 
concrete activities outlined here could be summarized as the devel-
opment of robust, reproducible, scalable, user-friendly, integrated, 
QC-controlled, data analysis pipelines, ideally enabling the use of 
compatible cloud infrastructures, which in addition, could also be 
used for data storage. Infrastructure supporting efficient develop-
ment of such pipelines and workflows is also important, including 
tool repositories and documentation, workflow management sys-
tems and interfaces for accessing computational resources.
Cluster 5. Protein quantification and statistics. This topic encom-
passes the improvement of protein inference in shotgun proteom-
ics approaches, the use of peptides that match to more than one 
protein precursor, and enhanced data integration/harmonisation for 
quantitative proteomics. It was perceived by many attendees that, 
although many of these issues are often considered solved, there are 
still many improvements possible in this area.
Cluster 6. Metadata, standardisation, annotation, and data 
management. This topic also includes the improvement in the 
annotation of proteomics datasets, in particular in data repositor-
ies like PRIDE (to facilitate public data reuse by third parties), the 
development and/or extension of existing Laboratory Information 
Management Systems (LIMS), standard data formats, and guide-
lines summarising best practises for data management, following 
FAIR principles.
The rest of the areas discussed got only one or two votes from the 
attendees, and included activities related to interactomics, struc-
tural proteomics, metabolomics, metaproteomics, the development 
of benchmarking datasets, and training efforts. Finally, it is worth 
highlighting an additional proposal for the creation of a repository 
for tool-related ideas.
Alignment between ELIXIR activities and the needs of the 
proteomics community
As mentioned in the ‘Methods’ section, ELIXIR activities are cur-
rently structured in five platforms (Data, Tools, Interoperability, 
Compute and Training) and four longitudinal use cases (Human 
data, Rare diseases, Marine metagenomics and Plant sciences) 
(Figure 2). Our preferred option is that proteomics becomes the 
main focus of one additional ELIXIR use case in the near future. 
If there is no scope for proteomics to have its own use case, other 
options could be possible, for instance the integration of proteom-
ics activities into the existing ELIXIR use cases. We think that the 
current use cases, heavily focused on genomics data, would also 
benefit from having a “multi-omics” perspective. Out of the exist-
ing cases, Human data would be an obvious choice. The other 
three could also benefit from proteomics activities: Rare diseases 
(clinical proteomics), Marine metagenomics (metaproteomics), and 
Plant sciences (plant proteomics).
In any case, and without considering specific use cases, it is clear 
that there are several topics that, in our opinion, would fit very well 
into the scope of the current five ELIXIR platforms:
1- Data platform. Metadata, standardisation, annotation and data 
management activities (Cluster 6), and “multi-omics” approaches 
(Cluster 1), involving data integration efforts from different omics 
data types, would be highly relevant in this context. Moreover, QC 
efforts (Cluster 3) are essential for all such types of data re-use. 
Indeed, data re-use is a very important aspect in proteomics data, 
as only 30–40% of the acquired data is typically exploited14. This 
creates extremely exciting opportunities for proteomics data re-use 
with specialized tools that can lead to the discovery of new biologi-
cal information21.
2- Tools platform. In this platform, the overall aim would be to 
increase the visibility, quality and sustainability of proteomics soft-
ware developed following best practices. First of all, more proteom-
ics tools should be effectively included into the ELIXIR tool registry, 
and highlighted there appropriately. However, it is worth highlight-
ing that there are around 350 tools proteomics tools represented in 
this resource already. In addition, the development of improved and 
user-friendly quantification algorithms and tools, along with direct 
coupling to dedicated and performant statistical analysis (Cluster 
5), also connects directly to the ELIXIR tools platform. Other pos-
sible activities would be related to Cluster 4, and would involve the 
improvement of the description and sharing of proteomics work-
flows, facilitating the encapsulation of workflows, data and tools 
into proteomics software containers that could be shared across 
ELIXIR, taking advantage of existing resources. Finally, the pro-
posed idea in the meeting to create of a repository for tool-related 
ideas, would also be applicable in the wider ELIXIR context.
3- Interoperability platform. Obviously, the activities of this plat-
form are very relevant in the case of “multi-omics” approaches 
(Cluster 1), for instance the development of data standards for 
these type of approaches, e.g. to enable better data integration and 
visualisation. A close connection can also be made to metabo-
lomics with regards to QC (Cluster 3), as the main technology of 
choice (mass spectrometry) is shared between these two fields.
4- Compute platform. Workflow analysis pipelines and activities 
related to the development of cloud infrastructures (Cluster 4) and 
QC activities (Cluster 3) should be highlighted here. This would 
involve different pieces of infrastructure supporting the efficient 
development of such workflows, e.g. the EDAM ontology and the 
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ELIXIR tool registry15, open data formats, and workflow manage-
ment systems, among others.
It is important to note that, although originally set up in the Data 
platform, the proteomics ELIXIR implementation study mentioned 
in the ‘Introduction’ section aims to make a first step forward in this 
direction, for the popular shotgun (MS/MS) approaches. As a proof 
of concept, these pipelines will be deployed first in the EMBL-
EBI “Embassy Cloud”, a cloud infrastructure based in the Open 
Stack operating system, with the idea that in the future they can be 
made available in other cloud systems (e.g. Amazon EC2, Google 
Cloud, Microsoft Azure), so that the developed pipelines can be 
freely reused by any interested researcher in the community. In the 
context of the implementation study, the pipelines are connected 
to the PRIDE database, bringing the analysis tools closer to the 
data as datasets become larger in size and complexity. This trend 
is ongoing for other omics technologies in the context of ELIXIR: 
for instance, the pipelines developed in the context of the Marine 
metagenomics use case22.
5- Training platform. ELIXIR is already working actively in coordi-
nating training activities across Europe (e.g. the already mentioned 
TeSS portal). Although training was not specifically highlighted as 
one of the main areas for future development during the meeting, 
the reason is that everyone assumes that this is implicitly a key need 
in all bioinformatics fields. While excellent training courses and 
workshops have already been created in the field, a higher degree of 
coordination across Europe should be achieved for bioinformatics 
training activities, and in particular for computational proteomics 
topics, possibly in coordination with other fields such as metabo-
lomics (see next section).
Connection to metabolomics and other ESFRIs
As mentioned already, metabolomics and proteomics share a com-
mon experimental platform: mass spectrometry. A parallel effort is 
currently ongoing to integrate metabolomics activities in ELIXIR. 
There are many topics of common interest where both fields could 
benefit from a closer interaction: e.g. the development of common 
software (for QC, data visualisation, signal processing, to name 
but a few) and open data standards. Some initiatives are already 
working towards this goal, e.g. the computational mass spectrom-
etry group (http://compms.org/), and some recent activities recently 
carried out by the PSI, but a lot of work remains to be done. One 
concrete proposal would be to coordinate efforts concerning train-
ing activities. ELIXIR would be an ideal platform to enable this 
coordination effort.
Coming back to the proteomics field, PRIME-XS (http://www.
primexs.eu) was a four-year Infrastructure project funded by the 
EU FP7 Programme (2011–2015), coordinated by Prof. Albert 
Heck. The main aim of PRIME-XS was to provide funded access 
to an infrastructure of state-of-the-art proteomics technology to 
the European biological and biomedical research community. It 
is anticipated that future tailored EU H2020 infrastructure grant 
calls might provide an opportunity to create a second iteration 
of this successful project. The potential synergies with ELIXIR, 
considering the outlined activities in this white paper, would be 
obvious at different levels, for instance the provision of a cloud 
computing infrastructure to store and analyse the acquired data in 
a scalable and reproducible way, and the development of pipelines 
to allow data integration between proteomics and other omics data 
types.
Conclusions
We hope that this white paper acts as a guide to achieve the over-
all goal of integrating proteomics into ELIXIR. In our opinion, 
this would not only make perfect sense from a scientific point of 
view (proteomics information provides an essential ingredi-
ent in a “full picture” of life), but also because it would enable 
computational proteomics to work in close contact with bioin-
formatics activities in other high-throughput fields, which will 
undoubtedly trigger many possible interactions, exchanges, and 
exciting novel developments.
Competing interests
No competing interests were disclosed.
Grant information
The meeting was funded by funds provided by the ELIXIR Cen-
tral Hub (supported by EU H2020 Research Infrastructures). This 
activity is included in the ELIXIR Implementation Project entitled 
‘Mining the Proteome: Enabling Automated Processing and 
Analysis of Large-Scale Proteomics Data’. 
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript. 
Acknowledgements
We want to acknowledge P. Velek (ELIXIR Hub) for his help in 
drafting Figure 2.
Supplementary material
Supplementary File 1: Detailed minutes of the meeting “The future of proteomics in ELIXIR”. 
Click here to access the data.
Supplementary File 2: Table S1: Table summarising the output of the open discussion at the meeting.
Click here to access the data.
Page 8 of 11
F1000Research 2017, 6:875 Last updated: 08 NOV 2017
References
1. Mallick P, Kuster B: Proteomics: a pragmatic perspective. Nat Biotechnol. 2010; 
28(7): 695–709.  
PubMed Abstract | Publisher Full Text 
2. Aebersold R, Mann M: Mass-spectrometric exploration of proteome structure 
and function. Nature. 2016; 537(7620): 347–55.  
PubMed Abstract | Publisher Full Text 
3. Menschaert G, Fenyö D: Proteogenomics from a bioinformatics angle: A growing 
field. Mass Spectrom Rev. 2015.  
PubMed Abstract | Publisher Full Text 
4. Cox J, Mann M: MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein 
quantification. Nat Biotechnol. 2008; 26(12): 1367–72.  
PubMed Abstract | Publisher Full Text 
5. Röst HL, Sachsenberg T, Aiche S, et al.: OpenMS: a flexible open-source 
software platform for mass spectrometry data analysis. Nat Methods. 2016; 
13(9): 741–8.  
PubMed Abstract | Publisher Full Text 
6. Barsnes H, Vaudel M, Colaert N, et al.: compomics-utilities: an open-source 
Java library for computational proteomics. BMC Bioinformatics. 2011; 12: 70. 
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Vaudel M, Burkhart JM, Zahedi RP, et al.: PeptideShaker enables reanalysis of 
MS-derived proteomics data sets. Nat Biotechnol. 2015; 33(1): 22–4.  
PubMed Abstract | Publisher Full Text 
8. Vizcaino JA, Csordas A, del-Toro N, et al.: 2016 update of the PRIDE database 
and its related tools. Nucleic Acids Res. 2016; 44(D1): D447–56.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Deutsch EW, Csordas A, Sun Z, et al.: The ProteomeXchange consortium in 
2017: supporting the cultural change in proteomics public data deposition. 
Nucleic Acids Res. 2017; 45(D1): D1100–D6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Deutsch EW, Albar JP, Binz PA, et al.: Development of data representation 
standards by the human proteome organization proteomics standards 
initiative. J Am Med Inform Assoc. 2015; 22(3): 495–506.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11. Uhlén M, Fagerberg L, Hallström BM, et al.: Proteomics. Tissue-based map of the 
human proteome. Science. 2015; 347(6220): 1260419.  
PubMed Abstract | Publisher Full Text 
12. UniProt Consortium: UniProt: a hub for protein information. Nucleic Acids Res. 
2015; 43(Database issue): D204–12.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13. Lane L, Argoud-Puy G, Britan A, et al.: neXtProt: a knowledge platform for 
human proteins. Nucleic Acids Res. 2012; 40(Database issue): D76–83.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Martens L, Vizcaíno JA: A Golden Age for Working with Public Proteomics Data. 
Trends Biochem Sci. 2017; 42(5): 333–341.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15. Ison J, Rapacki K, Ménager H, et al.: Tools and data services registry: a 
community effort to document bioinformatics resources. Nucleic Acids Res. 
2016; 44(D1): D38–47.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Willems S, Bouyssié D, David M, et al.: Proceedings of the EuBIC Winter School 
2017. J Proteomics. 2017; 161: 78–80.  
PubMed Abstract | Publisher Full Text 
17. Durinx C, McEntyre J, Appel R, et al.: Identifying ELIXIR Core Data Resources 
[version 2; referees: 2 approved]. F1000Res. 2016; 5: pii: ELIXIR-2422.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Eijssen L, Evelo C, Kok R, et al.: The Dutch Techcentre for Life Sciences: 
Enabling data-intensive life science research in the Netherlands [version 2; 
referees: 2 approved, 1 approved with reservations]. F1000Res. 2015; 4: 33. 
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Wilkinson MD, Dumontier M, Aalbersberg IJ, et al.: The FAIR Guiding Principles 
for scientific data management and stewardship. Sci Data. 2016; 3: 160018. 
PubMed Abstract | Publisher Full Text | Free Full Text 
20. Smith LM, Kelleher NL, Consortium for Top Down Proteomics: Proteoform: a 
single term describing protein complexity. Nat Methods. 2013; 10(3): 186–7. 
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Vaudel M, Verheggen K, Csordas A, et al.: Exploring the potential of public 
proteomics data. Proteomics. 2016; 16(2): 214–25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Robertsen EM, Denise H, Mitchell A, et al.: ELIXIR pilot action: Marine 
metagenomics – towards a domain specific set of sustainable services 
[version 1; referees: 1 approved, 2 approved with reservations]. F1000Res. 
2017; 6: (ELIXIR)(70).  
Publisher Full Text 
Page 9 of 11
F1000Research 2017, 6:875 Last updated: 08 NOV 2017
 Open Peer Review
  Current Referee Status:
Version 1
 05 July 2017Referee Report
doi:10.5256/f1000research.12693.r23920
 Chuming Chen
Center for Bioinformatics and Computational Biology, University of Delaware, Newark, DE, USA
This white paper presents a framework for integrating computational proteomics into ELIXIR as the result
of a strategy meeting on ‘The Future of Proteomics in ELIXIR’ that took place in March 2017 in Tübingen
(Germany). The meeting discussions lead to six priority areas: Multi-omics approaches; Proteoforms and
PTMs; Quality Control (QC) activities; Data analysis workflows and cloud computing;
Protein quantification and statistics; Metadata, standardization, annotation, and data management. The
priority areas are well aligned with the current ELIXIR platforms: Data platform; Tools platform;
Interoperability platform; Compute platform; Training platform and can be integrated into ELIXIR. The
paper is well structured and written.
Minor change: 
On page 7 of PDF version of paper, paragraph "2 - Tools platform ...":
"it is worth highlighting that there are around 350 tools proteomics tools represented in this resource
already", the first "tools" should be removed.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 28 June 2017Referee Report
doi:10.5256/f1000research.12693.r23454
Page 10 of 11
F1000Research 2017, 6:875 Last updated: 08 NOV 2017
 doi:10.5256/f1000research.12693.r23454
 Felix Elortza
CIC bioGUNE, CIBERehd, ProteoRed-ISCIII, Derio, Spain
Proteomics has reached a point in which bioinformatics is of paramount importance for the process to
extract the maximum information out of the enormous amount of data obtained in practically any study.
The scientific community in general and proteomics in particular is eager to get new and effective
solutions that may implement that way. In this white paper manuscript, Vizcaino  explain the ELIXIRet al. 
initiative and the importance of integrating proteomics in this European Research Infrastructure. Authors
cover in a detailed way what was covered on the meeting that took place in Tübingen (Germany) on
February 2017 under the name “The future of proteomics in ELIXIR”. The paper is well written and
structured. Conclusions are clearly stated.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes
Are all factual statements correct and adequately supported by citations?
Yes
Are arguments sufficiently supported by evidence from the published literature?
Yes
Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
Page 11 of 11
F1000Research 2017, 6:875 Last updated: 08 NOV 2017
